Ncardia is a biotechnology company that specializes in the development and commercialization of human iPSC (induced pluripotent stem cell)-derived cardiovascular and neurological cell models for drug discovery, safety pharmacology, and disease modeling. Their offerings include high-quality human iPSC-derived cells, assay development services, and drug screening platforms. Ncardia's technologies enable pharmaceutical companies and research institutions to conduct more predictive and efficient preclinical testing, ultimately accelerating the development of new therapeutics.
